C.R. Bard, Inc. lost its appeal of a jury’s $2 million verdict in Fourth Circuit appellate court on Thursday. The court found that the medical device manufacturer was, in fact, responsible for the injuries the plaintiff suffered after she was implanted with the company’s transvaginal mesh device. In the appeal, Bard claimed that the district court wrongly excluded evidence regarding the FDA’s approval of its product. The court decided that the approval of the product did not adequately represent its safety, only how well it matched something already on the market.